A PhD-level researcher with 30+ years of pharma industry experience, mostly in women’s health (some of my publications are listed below). In the past, I evaluated clinical data to justify the development of Ortho Tri-Cyclen Lo® and was a co-inventor of this top-selling oral contraceptive in the US. Tri-Cyclen Lo’s prescriptions share of 9% is translated into $1.8B/year in today’s market. I am the Founder, President, and Chief Scientific Officer of ARSTAT Pharmaceuticals. The specialty pharma company focuses on significant unmet needs in women’s health: contraception for women with high BMI, treatment of uterine fibroids and endometriosis, and control of painful and heavy menstrual periods. The pipeline includes four drug candidates with proven efficacy and safety, protected by fourteen U.S. patents and a European (EPO) patent. Two products are Phase III-ready (confirmed by the FDA), and two other products are ready for Phase IIb. An addressable U.S. market is approximately 50 million women, with projected peak U.S. gross sales exceeding $3.4 billion. This is arguably one of the best pharmaceutical portfolios in women’s health.Recent Roe v. Wade development makes the need for highly effective birth control more urgent than ever. ARSTAT Pharmaceuticals addresses this public health priority by developing, for the first time, an oral contraceptive for women with above-normal weight.Thirty million U.S. women search for birth control, and 20 million of these women are overweight or with obesity. By far the most popular method, oral contraceptives do not work well in this population due to poor efficacy and troublesome side effects. The company’s lead product - Nuvocept – will return the pill to these women as a trusted and safe option, greatly reducing the number of unwanted pregnancies, some of which result in abortions.The FDA has recognized the large unmet contraceptive need, accepted Nuvocept efficacy and safety projections, confirmed its Phase III-ready status, and endorsed a pathway to an unprecedented label for women with high BMI. Protected by six granted U.S. patents and an E.U. patent, Nuvocept is < $20M and 3.5 years away from FDA approval. Top experts consider Nuvocept a >$2B/year U.S. opportunity. Significant ex-US (particularly E.U.) sales are also expected. The company is raising money ahead of an appealing IPO. I am reaching out to investors, strategic partners, potential executives, and advisors. To learn more, please visit www.arstatinfo.com My contact information: email: arubin@arstatinc.com, cell phone: (347)385-0878.